Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year


IMPACT FACTOR 2016: 3.432

CiteScore 2016: 2.21

SCImago Journal Rank (SJR) 2016: 1.000
Source Normalized Impact per Paper (SNIP) 2016: 1.112

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 50, Issue 1 (Jan 2012)

Issues

Circulating levels of HER-2/neu oncoprotein in breast cancer

Rafael Molina / Jose M. Escudero
  • Laboratory of Biochemistry (Oncobiology Unit), School of Medicine, Hospital Clinic, Barcelona, Spain
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Montse Muñoz
  • Laboratory of Biochemistry (Oncobiology Unit), School of Medicine, Hospital Clinic, Barcelona, Spain
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Jose M. Augé
  • Laboratory of Biochemistry (Oncobiology Unit), School of Medicine, Hospital Clinic, Barcelona, Spain
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Xavier Filella
  • Laboratory of Biochemistry (Oncobiology Unit), School of Medicine, Hospital Clinic, Barcelona, Spain
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2012-01-04 | DOI: https://doi.org/10.1515/cclm.2011.822

Abstract

HER-2/neu, also known as c-erbB-2/neu, is an oncogene located in chromosome 17 which encodes HER-2/neu, a transmembrane protein belonging to the EGFR family. The external domain of this protein is released by the cell and can be studied in serum by immunoassay. HER-2/neu in serum is a specific tumor marker and only slight elevations may be found in the absence of malignancy, mainly in association with liver diseases. Likewise, the highest concentrations of this oncoprotein are found in patients with breast cancer, but lower concentrations may be found in other malignancies, particularly ovarian, prostate and lung cancer (mainly adenocarcinomas). HER-2/neu assay sensitivity in patients with untreated primary loco-regional breast cancer is <10% and seems to be related to overexpression in tissue as well as to the most important prognostic factors: tumor size and nodal involvement. Serial HER-2/neu determinations after surgery seem to be useful in the early diagnosis of recurrence, mainly in patients with HER-2/neu overexpression in tissue, but additional studies are necessary to confirm these results. HER-2/neu sensitivity (proportion of patients with abnormal values) in patients with metastasis is around 40%–45%, with a clear relationship to tissue overexpression and to site (higher in visceral metastases) and number of metastases. The clinical utility of HER-2/neu in patients with advanced disease is mainly for therapeutic monitoring. Likewise, in most of the studies published, a relationship has been found between serum HER-2/neu levels (either pretreatment or at follow-up) with tumor response.

Keywords: breast cancer; CA 15.3; carcinoembryonic antigen (CEA); HER-2/neu; oncoproteins; tumor markers

About the article

Corresponding author: Rafael Molina, MD, PhD, Oncobiology Unit, Laboratory of Biochemistry and Molecular Biology, Hospital Clinic, Villarroel 170, Barcelona 08036, Spain


Received: 2011-07-25

Accepted: 2011-11-20

Published Online: 2012-01-04

Published in Print: 2012-01-01


Citation Information: Clinical Chemistry and Laboratory Medicine, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/cclm.2011.822.

Export Citation

©2011 by Walter de Gruyter Berlin Boston. Copyright Clearance Center

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Lulu Wang
Sensors, 2017, Volume 17, Number 7, Page 1572
[2]
Marianne Nordlund Broughton, Arne Westgaard, Elisabeth Paus, Miriam Øijordsbakken, Karoline J Henanger, Bjørn Naume, and Trine Bjøro
Tumor Biology, 2017, Volume 39, Number 6, Page 101042831770743
[3]
Suzanne A Eccles, Eric O Aboagye, Simak Ali, Annie S Anderson, Jo Armes, Fedor Berditchevski, Jeremy P Blaydes, Keith Brennan, Nicola J Brown, Helen E Bryant, Nigel J Bundred, Joy M Burchell, Anna M Campbell, Jason S Carroll, Robert B Clarke, Charlotte E Coles, Gary JR Cook, Angela Cox, Nicola J Curtin, Lodewijk V Dekker, Isabel dos Santos Silva, Stephen W Duffy, Douglas F Easton, Diana M Eccles, Dylan R Edwards, Joanne Edwards, D Gareth Evans, Deborah F Fenlon, James M Flanagan, Claire Foster, William M Gallagher, Montserrat Garcia-Closas, Julia M W Gee, Andy J Gescher, Vicky Goh, Ashley M Groves, Amanda J Harvey, Michelle Harvie, Bryan T Hennessy, Stephen Hiscox, Ingunn Holen, Sacha J Howell, Anthony Howell, Gill Hubbard, Nick Hulbert-Williams, Myra S Hunter, Bharat Jasani, Louise J Jones, Timothy J Key, Cliona C Kirwan, Anthony Kong, Ian H Kunkler, Simon P Langdon, Martin O Leach, David J Mann, John F Marshall, Lesley Ann Martin, Stewart G Martin, Jennifer E Macdougall, David W Miles, William R Miller, Joanna R Morris, Sue M Moss, Paul Mullan, Rachel Natrajan, James PB O’Connor, Rosemary O’Connor, Carlo Palmieri, Paul D P Pharoah, Emad A Rakha, Elizabeth Reed, Simon P Robinson, Erik Sahai, John M Saxton, Peter Schmid, Matthew J Smalley, Valerie Speirs, Robert Stein, John Stingl, Charles H Streuli, Andrew N J Tutt, Galina Velikova, Rosemary A Walker, Christine J Watson, Kaye J Williams, Leonie S Young, and Alastair M Thompson
Breast Cancer Research, 2013, Volume 15, Number 5
[4]
Gaetano Aurilio, Maria Teresa Sandri, Giancarlo Pruneri, Laura Zorzino, Edoardo Botteri, Elisabetta Munzone, Laura Adamoli, Giuseppina Facchi, Daniela Cullurà, Elena Verri, Maria Cossu Rocca, Stefano Zurrida, Roberto Iacovelli, and Franco Nolè
Future Oncology, 2016, Volume 12, Number 17, Page 2001
[5]
Dorit Di Gioia, Marie Dresse, Doris Mayr, Dorothea Nagel, Volker Heinemann, Steffen Kahlert, and Petra Stieber
Clinica Chimica Acta, 2014, Volume 430, Page 86
[6]
Patricia Diana Sørensen, Erik Hugger Jakobsen, Jonna Skov Madsen, Eva Brix Petersen, Rikke Fredslund Andersen, Birthe Østergaard, and Ivan Brandslund
Journal of Cancer Research and Clinical Oncology, 2013, Volume 139, Number 6, Page 1005

Comments (0)

Please log in or register to comment.
Log in